Compare IQV & DHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | DHI |
|---|---|---|
| Founded | 1982 | 1978 |
| Country | United States | United States |
| Employees | 93000 | 14341 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1B | 41.7B |
| IPO Year | 2013 | 1995 |
| Metric | IQV | DHI |
|---|---|---|
| Price | $262.33 | $145.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 14 |
| Target Price | ★ $227.13 | $166.08 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 05-05-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.19% |
| EPS Growth | ★ 4.67 | N/A |
| EPS | 1.61 | ★ 7.45 |
| Revenue | $9,739,000,000.00 | ★ $34,250,400,000.00 |
| Revenue This Year | $6.77 | $0.05 |
| Revenue Next Year | $5.89 | $5.85 |
| P/E Ratio | $162.43 | ★ $20.03 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $154.50 | $131.75 |
| 52 Week High | $262.51 | $183.62 |
| Indicator | IQV | DHI |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 45.52 |
| Support Level | $159.91 | $138.27 |
| Resistance Level | N/A | $153.01 |
| Average True Range (ATR) | 7.47 | 3.60 |
| MACD | 0.69 | 0.02 |
| Stochastic Oscillator | 92.06 | 3.98 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
D.R. Horton is the largest homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. The firm has majority ownership of Forestar Group, a publicly traded residential lot development company. D.R. Horton's headquarters are in Arlington, Texas.